Intra-Cellular Therapies (NASDAQ: ITCI) reported Q2 EPS of ($0.16), $0.03 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $161.4 million versus the consensus estimate of $158.1 million.

GUIDANCE:

Intra-Cellular Therapies sees FY2024 revenue of $650-680 million, versus the consensus of $662.2 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.